GeneTx and Ultragenyx Announce First Patient Dosed in Canada in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome October 7, 2021
Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases October 7, 2021
Atalanta Therapeutics Strengthens Leadership Team with Key Appointments in R&D and Corporate Development October 7, 2021
Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab Biosimilar Candidate CHS-201 to Reference Product Lucentis® (Ranibizumab) in the Treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Presented at Retina Society Annual Scientific Meeting October 4, 2021